Akasa, Jet Airways 2.0 may add to the woes of Indian aviation industry: HSBC Global Research

While IndiGo is expected to report a Rs 310 crore loss, SpiceJet is expected to report losses to the tune of Rs 170 crore during the recently concluded quarter.

Moneycontrol News

January 14, 2022 / 07:35 PM IST

In its report titled 'Indian Aviation, 2022: A year of two halves', HSBC Global Research said that while the aviation sector might see a recovery in demand in April-June 2022, optimism around the sector will be short-lived as new players plan to start operations from July.

The struggles of the Indian aviation industry are unlikely to ease in the coming few years, according to HSBC Global Research. The research house expects the entry of two new carriers, Akasa and Jet Airways 2.0, to weaken the health of the domestic airlines due to upcoming expected fare wars and excess supply in the Indian market.

In its report titled 'Indian Aviation, 2022: A year of two halves', HSBC Global Research said that while the aviation sector might see a recovery in demand in April-June 2022, optimism around the sector will be short-lived as new players plan to start operations from July.

"Amidst all these challenges, investors are concerned about the yield outlook.... we think the fare war could be an obvious outcome of excess supply in the market. On our calculation, the industry could add 80-85 aircraft this year which could increase the gap between demand and supply, adding pressure on the load factor and yield," the research house said.

Furthermore, it expects InterGlobe Aviation-operated IndiGo and SpiceJet to report steep losses during the December quarter.

While IndiGo is expected to report a Rs 310 crore loss, SpiceJet is expected to report losses to the tune of Rs 170 crore during the recently concluded quarter.

COVID-19 Vaccine

Frequently Asked Questions

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

Show